ArticleCancer research2026

Catalytic Inhibition of p300 Preferentially Targets IRF4 Oncogenic Activity and Tumor Growth in Multiple Myeloma.

W Frank Lenoir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.